Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (PCVX) is a clinical-stage biopharmaceutical leader developing next-generation vaccines against invasive bacterial diseases. This page provides investors and stakeholders with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Access official press releases and verified news covering Vaxcyte's innovative pipeline, including its VAX-24 and VAX-31 pneumococcal conjugate vaccine candidates engineered using the proprietary XpressCF™ platform. Stay informed about advancements in broad-spectrum protection strategies targeting pneumococcal disease and other bacterial infections.
Key content categories include clinical trial results, manufacturing partnerships, intellectual property updates, and scientific presentations. All materials are sourced directly from company filings and accredited industry publications to ensure accuracy.
Bookmark this page for streamlined access to essential updates about Vaxcyte's mission to redefine vaccine development through advanced synthetic biology and carrier-sparing conjugate technologies.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The event aims to showcase Vaxcyte's innovative vaccine development efforts, including its lead candidate, VAX-24, a preclinical pneumococcal conjugate vaccine designed for preventing invasive pneumococcal disease. A live webcast will be available through the company's website, with a replay offered for 30 days post-conference. Vaxcyte is focused on creating novel vaccines to address common infectious diseases globally.
Vaxcyte, Inc. (Nasdaq: PCVX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $20.7 million for Q4 and $89.2 million for the year. The company announced a revised timeline for its VAX-24 IND application submission, now expected between January and June 2022, due to manufacturing constraints. Key advancements included new immunogenicity data for its VAX-XP program and the final candidate nomination for VAX-A1. Vaxcyte's cash position increased to $386.2 million, supported by its IPO and Series D financing in 2020.
Vaxcyte, Inc. (Nasdaq: PCVX) will report its financial results for Q4 and the full year 2020 after market close on March 29, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss the results and provide a business update. Vaxcyte develops innovative vaccines aimed at preventing major infectious diseases, leveraging its cell-free protein synthesis platform, XpressCF. The lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine. Additional candidates include VAX-XP, VAX-A1, and VAX-PG.
Vaxcyte published preclinical data for its novel Group A Streptococcus vaccine candidate, VAX-A1, in the journal Infectious Microbes & Diseases. This vaccine aims to combat Group A Strep, a leading cause of bacterial infections, including strep throat, which significantly contributes to global antibiotic prescriptions. The study exhibited that the vaccine could effectively protect against Group A Strep infections in mouse models without cross-reactivity to human tissues. Vaxcyte is advancing toward a global health solution amid rising antibiotic resistance concerns.
Vaxcyte, Inc. has announced the promotion of Andrew Guggenhime to President and Chief Financial Officer, effective January 1, 2021. This transition reflects the company's leadership evolution as it aims to scale operations and advance its vaccine pipeline, especially the pneumococcal vaccine candidate VAX-24. Guggenhime, who joined Vaxcyte in May 2020, brings over two decades of financial and operational experience in the healthcare sector.
Vaxcyte focuses on developing innovative vaccines to combat infectious diseases globally, leveraging its cell-free protein synthesis platform for vaccine creation.
Vaxcyte, formerly SutroVax, announced participation in a fireside chat at the Evercore ISI 3rd Annual HealthCONx conference on December 2, 2020, at 1:50 PM ET. The event aims to discuss the company’s innovative vaccine developments targeting widespread infectious diseases. A live webcast will be available on the company’s website, with a replay offered for 30 days post-event. Vaxcyte is advancing several candidates, including VAX-24, a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease.
Vaxcyte announced its Q3 2020 financial results, highlighting a net loss of $21 million compared to $11.3 million in Q3 2019. The company’s cash position improved significantly to $397 million, up from $59 million at the end of 2019, following its IPO and Series D financing. Vaxcyte reported R&D expenses of $16.4 million, primarily due to increased manufacturing costs for its VAX-24 program, and G&A expenses rose to $4.9 million. Key milestones include an anticipated IND filing for VAX-24 in the second half of 2021 and ongoing progression in its vaccine pipeline.
Vaxcyte, a next-generation vaccine company, announced its participation at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 PM ET. The presentation aims to showcase Vaxcyte's innovative vaccine development efforts for preventing common infectious diseases. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event. Vaxcyte's pipeline includes vaccines for pneumococcal disease, Group A Strep infections, and periodontal disease, leveraging a unique cell-free protein synthesis platform.
Vaxcyte, formerly known as SutroVax, announced participation in the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 11:00 a.m. ET. The company aims to enhance global health through innovative vaccines targeting infectious diseases. Their lead candidate, VAX-24, is a preclinical 24-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. Vaxcyte's platform, XpressCF™, enables advanced vaccine development, including candidates for Group A Strep infections and periodontal disease. Access the live webcast and replay via their website.
